



2024 Sustainability Highlights

Event for investors and analysts


28 May 2025



Forward-looking statements

This document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, statements about expected revenues, margins, earnings per share or other financial or other measures. Although the Group believes its expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. The forward-looking statements reflect knowledge and information available at the date of preparation of this document and the Group undertakes no obligation to update these forward-looking statements. The Group identifies the forward-looking statements by using the words ‘anticipates’, ‘believes’, ‘expects’, ‘intends’ and similar expressions in such statements. Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond the Group’s control, include, among other things: the risk of failure or delay in delivery of pipeline or launch of new medicines; the risk of failure to meet regulatory or ethical requirements for medicine development or approval; the risk of failures or delays in the quality or execution of the Group’s commercial strategies; the risk of pricing, affordability, access and competitive pressures; the risk of failure to maintain supply of compliant, quality medicines; the risk of illegal trade in the Group’s medicines; the impact of reliance on third-party goods and services; the risk of failure in information technology or cybersecurity; the risk of failure of critical processes; the risk of failure to collect and manage data and AI in line with legal and regulatory requirements and strategic objectives; the risk of failure to attract, develop, engage and retain a diverse, talented and capable workforce; the risk of failure to meet our sustainability targets, regulatory requirements and stakeholder expectations with respect to the environment; the risk of the safety and efficacy of marketed medicines being questioned; the risk of adverse outcome of litigation and/or governmental investigations; intellectual property risks related to the Group’s products; the risk of failure to achieve strategic plans or meet targets or expectations; the risk of geopolitical and/or macroeconomic volatility disrupting the operation of our global business; the risk of failure in internal control, financial reporting or the occurrence of fraud; the risk of unexpected deterioration in the Group’s financial position; the risk of foreign exchange rate movements impacting our financial condition or results of operations; and the impact that global and/or geopolitical events may have or continue to have on these risks, on the Group’s ability to continue to mitigate these risks, and on the Group’s operations, financial results or financial condition. Nothing in this document, or any related presentation/webcast, should be construed as a profit forecast.





Sustainability @ AstraZeneca

Pam Cheng


EXECUTIVE VICE PRESIDENT,
GLOBAL OPERATIONS, IT &
CHIEF SUSTAINABILITY OFFICER



Ambition – \$80bn Total Revenue by 2030 & sustained 2030+ growth

Working on “today, tomorrow and the day after”

Illustrative only, not to scale



Note: Ambition to achieve \$80bn in Total Revenue by 2030 is risk-adjusted, based on latest long-range plan – see ‘Forward looking statements’ slide for forward looking statement.

4 Medicines and assets listed reflect key contributors to 2030 Total Revenue ambition; however, this list is not exhaustive. Medicines and assets listed in alphabetical order and sorted by therapy area.

1. NME ambition tracking from date of first regulatory approval, dated from November 2022, total as of May 2025. CVRM = Cardiovascular, Renal & Metabolism; R&I = Respiratory & Immunology; V&I = Vaccines & Immune Therapies; M&A = mergers and acquisitions; ADC = antibody-drug conjugate; IO = immuno-oncology.



Sustainability is core part of achieving our ambitions



Science & innovation

- Invest in new technologies and modalities
- Leverage global R&D network




Growth & therapy area leadership

- Transform patient outcomes through novel medicines and combinations



Global footprint

- Broad-based network
- Differentiated Emerging Markets presence



Sustainability

- Build a healthy future for people, society and the planet, underpinned by governance and ethics



Progress in 2024 – action-oriented leadership in Sustainability

Access to Healthcare

90.4m

reached through philanthropic programmes¹

>156,000

healthcare workers trained²

14.2m

people reached by patient access programmes³

Environmental Protection

77.5%

reduction in Scope 1 and Scope 2 greenhouse gas emissions since 2015

23%

reduction in water usage since 2015

13%

reduction in total waste since 2015

Ethics and Transparency

100%

active employees trained on employee Code of Conduct

10 countries

launched supplier diversity programmes in 2024

50.6%

of senior middle management roles are occupied by women

25/27

of sustainability targets are 'green' meaning they are 'on plan' or 'target met'

84%

of employees believe that AstraZeneca is a great place to work

4x recognition

for inclusion and diversity efforts



Key sustainability topics embedded across our enterprise following double materiality assessment

Material topics include:

> Accessible and affordable healthcare

> Patient safety and product quality

> Business conduct

> Pollution

> Climate change

> Sustainable innovation

> Cybersecurity and data privacy

> Talent attraction and retention

I. **Identify sustainability related impacts, risks and opportunities**
via sector guidance and benchmarking and stakeholder feedback

II. **Assess impacts, risks and opportunities**
based on due diligence findings, internal assessments and research

III. **Refined and validated assessment**
via internal and external stakeholder feedback from patient groups, suppliers, investors, academia and other organisations



Our evolved Sustainability strategy at AstraZeneca



How we make a sustainable impact:

through the power of science and innovation, we are taking action on climate and nature, health equity and health systems resilience

How we do business:

we are guided by our values and invest in our people to create long-term value, resilience and trust by operating responsibly, ethically and with robust governance

Our Sustainability impact

through the power of science and innovation, we are taking action on climate and nature, health equity and health systems resilience




Aiming to reduce our impact on the planet and help restore our natural world through climate and nature action

Ambition Zero Carbon

Reduce absolute Scope 1 & 2 GHG emissions by 98% by 2026

Reduce absolute Scope 3 GHG emissions by 50% by 2030¹ & by 90% by 2045



Industry-first renewables energy agreement:

- Partnered with GSK, Takeda and nine suppliers
- Unlocks c.225 GWh of renewable electricity
- Potential emission savings 250,000 tonnes/year



Demonstrating our commitment to Scope 3 reduction with first-to-market next-generation propellant

High global unmet need

78%

of inhaled medicines used globally are pMDIs

Next-generation propellant

99.9%

less global warming potential (GWP) vs. current propellant



BREZTRI[®]
AEROSPHERE[®]

1st

industry-wide approval for Breztri/Trixexo with next-generation propellant (NGP)

~20%

of Scope 3 footprint addressed with next-generation propellant

On-track

to transition broader portfolio by 2030



approval granted for *Breztri/Trixexo* in UK



ongoing reviews for *Breztri* in EU, China and other geographies




Our increasing focus on Nature

Early adopters of TNFD:



L	LOCATE the interface with nature
E	EVALUATE dependencies and impacts
A	ASSESS risks and opportunities
P	PREPARE to respond and report

Following the SBTN AR3T Framework:



40m
trees planted towards our 200 million target¹

23%
reduction in water usage since 2015

3
projects supported through our Climate Adaptation and Nature Fund



Aiming to deliver health equity impact across key focus areas

Science

Ensuring more individuals **can equitably benefit** from our trials, science and capabilities

- Genomics
- Clinical trial representation
- Open innovation

Healthcare delivery

Improving **equitable health outcomes**, focusing on early detection, precision diagnosis and guideline-concordant treatment

- Lung health programmes
- Healthy Heart Africa
- Rare diseases

Community investment


Addressing the **root causes of health inequities** by investing in underserved communities

- Young Health Programme
- Disaster relief
- STEM

Underpinned by capabilities and engagement to build trust with partners and purpose with employees



Driving early detection and intervention of disease through AI-powered partnerships



Improving lung cancer screening

Leveraging chest x-rays globally with 17% improvement in detecting lung nodules¹ and potential applicability in LMICs



Target achieved to screen **5 million** patients by 2025

Accelerating detection of amyloidosis

Validating in community setting to demonstrate earlier patient identification outside of hospital care

Developing AI software medical device to analyse echocardiogram videos



✓ FDA Clearance






✓ FDA BT²



Partnering along the entire patient journey to close care gaps and improve equitable outcomes

Care gaps exist across the entirety of the patient journey



Our vision:



working to remove barriers to healthcare to give **everyone** the chance to be **as healthy as possible**

Our impact:

positively impact **one billion people** by 2030, with **400 million** from underserved populations



Contributing to stronger, more resilient health systems to meet future needs



5 years of the Partnership for Health System Sustainability & Resilience (PHSSR)

>30 countries involved in the PHSSR



Supporting health systems that can meet health needs today and tomorrow

EU Sustainable Healthcare Financing


Facilitated the development of policy recommendations for sustainable EU-level healthcare funding



Partnership for
Health System Sustainability & Resilience


European Network on Climate & Health Education (ENCHE)

Founded by 38 leading European universities to integrate climate and health teaching into curricula

Supported by Sustainable Markets Initiative 

>10k

medical students equipped with skills to address the health impacts of climate change




How we do business


we are guided by our values and invest in our people to create long-term value, resilience and trust by operating responsibly, ethically and with robust governance




Our Values guide our behaviours to deliver life-changing medicines




We follow the science




We put patients first




We play to win



We do the right thing



We are entrepreneurial



Delivering high-quality product manufacturing across a broad-based global network



0 critical findings
from all health authority inspections in 2024

0 patient-level recalls

High product availability



Remaining vigilant and prioritising cybersecurity across our enterprise

Zero

material cyber-security incidents in 2024

Zero

material security breaches involving personal data in 2024

Continuous proactive discipline practices to prevent business disruption:



Layered controls and monitoring
via third-party and internal teams




Metrics and dashboards
to inform all levels of organisation



Rigorous testing, tracking and remediation



Threat and risk modeling



Transforming ways of working with AI across AstraZeneca

AI in action:

Discovery

- > Target identification
- > Development of novel therapeutic modalities


Diagnosis



Partnering to increase detection of disease

Delivery

↑ Increasing autonomy while decreasing our impact on the environment ↓



85% of small molecule programmes utilise AI and data science

qure.ai



qure.AI
driving detection of lung diseases

InVision
improving cardiac amyloidosis diagnosis

55% increase

in output at Wuxi, China plant, leading to a **44% lead time reduction** and **54% increase in productivity**

Enterprise AI Governance Framework

- informs process for acquiring and deploying AI
- aligns with international standards including:



EU Artificial Intelligence Act



NIST AI Risk Management Framework




Attracting, retaining and developing our talent



Employee relations

- **Engagement with workforce** through team meetings, local and global townhalls and internal social media platform
- **Employee-led initiatives** including voluntary Employee Resource Groups (ERGs)



84%

of employees believe that AstraZeneca is a great place to work



Talent acquisition

- **Investing in AI** eightfold.ai to source top talent and enable positive candidate/employee experience
- **15.5% hiring rate**
- **10.9% employee turnover**

1.3m

applications received for an average 24,800 roles each year



Recognition and development

- **Performance coaching** 84% of employees receive coaching from immediate manager
- **Development opportunities** with continuous learning and skill uplifting capabilities
- **Continuous recognition** 85% of employees recognized through CatAlyZe awards

88%

of employees believe that they have learned or improved a skill or have had a development opportunity in the last year



Q&A Session

with Sustainability Leadership Team



Pam Cheng

EXECUTIVE VICE PRESIDENT,
GLOBAL OPERATIONS,
INFORMATION TECHNOLOGY AND
CHIEF SUSTAINABILITY OFFICER



Stefan Weber

VICE PRESIDENT POLICY, PATIENT
ADVOCACY AND HEALTH EQUITY



Liz Chatwin

VICE PRESIDENT,
GLOBAL SUSTAINABILITY AND SHE



Heather Stewart

VICE PRESIDENT, ETHICS AND
TRANSPARENCY



Confidentiality Notice

This file is private and may contain confidential and proprietary information. If you have received this file in error, please notify us and remove it from your system and note that you must not copy, distribute or take any action in reliance on it. Any unauthorized use or disclosure of the contents of this file is not permitted and may be unlawful.

AstraZeneca PLC, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA, UK
+44(0)203 749 5000
www.astrazeneca.com

